https://siftingsignal.com/gisignals/What is worth knowing in GI this week. A SiftingSignal publication.https://siftingsignal.com/gisignals/2026-W29/https://siftingsignal.com/gisignals/2026-W29/Sat, 18 Jul 2026 20:04:34 +0000Issue 2, week of Jul 12, 2026: 17 papers. Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.; Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.; IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD.; A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model.; Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.; Recompensation of decompensated cirrhosis in a spectrum of metabolic-dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors.; Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.; Comparison of Fully Covered Self-Expanding Metal Stents and Liquid Nitrogen Spray Cryotherapy for Malignant Esophageal Adenocarcinoma: A Retrospective Cohort Study.https://siftingsignal.com/gisignals/2026-W26/https://siftingsignal.com/gisignals/2026-W26/Thu, 09 Jul 2026 16:47:07 +0000Issue 1, week of Jun 24, 2026: 29 papers. Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.; Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.; Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.; ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.; ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.; A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.; Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.; Eosinophilic Esophagitis and Autoimmune Thyroid Disease: A Population-Based Matched Cohort Study.